Novartis Remibrutinib Achieves Phase 3 Success in Relapsing Multiple Sclerosis
Efficacy in Two Confirmatory Trials Demonstrates Relapse Suppression
Novartis AG (NVS)'s oral BTK inhibitor remibrutinib met its primary endpoints in both Phase 3 REMODEL-1 and REMODEL-2 trials in patients with relapsing multiple sclerosis (RMS). In the two trials, approximately 2,000 patients were randomized 1:1 to receive remibrutinib 100mg or Aubagio (teriflunomide, a DHODH inhibitor) for up to 30 months. Remibrutinib showed superiority in annualized relapse rate (ARR) and inflammatory brain lesion outcomes. The consistent success of two independent confirmatory trials reduces the risk of a single trial's chance findings and supports global regulatory submissions.
Disability Progression and Safety Will Influence Commercial Potential
In an integrated pre-planned analysis, three-month confirmed disability progression (3mCDP) showed a positive trend, while six-month confirmed disability progression (6mCDP) achieved nominal statistical significance. Detailed ARR reduction rates and p-values are expected to be presented at the 2026 MSToronto meeting, so current evaluation is limited to top-line ranges. However, the absence of liver safety signals or Hy's Law cases in the overall development program involving more than 4,500 patients represents a key differentiator within the BTK class. This is particularly in contrast to Merck KGaA's evobrutinib, which failed Phase 3 development due to liver injury and efficacy issues.
BTK Competition is a Two-Horse Race Between Roche and Novartis
The direct competitor is Roche Holding (RHHBY)'s non-covalent BTK inhibitor fenebrutinib, which reduced ARR by 51.1% and 58.5% in Phase 3 FENhance-1 and FENhance-2 trials, respectively, compared to Aubagio. Sanofi (SNY)'s tolebrutinib (Cenrifki, a BTK inhibitor) received European approval on June 23, 2026, for relapse-free secondary progressive multiple sclerosis (SPMS), but failed to meet its endpoints in relapsing MS trials. Current standard-of-care therapies include Roche's Ocrevus (ocrelizumab, a CD20-targeting antibody), Novartis' Kesimpta (ofatumumab, a CD20-targeting antibody), and Aubagio. Therefore, remibrutinib must demonstrate injectable-level efficacy, oral convenience, and liver safety to drive prescription switching.
Expanding into MS Based on Existing Approval
Remibrutinib is already marketed under the brand name Rhapsido for chronic spontaneous urticaria (CSU) in adults who have had an inadequate response to antihistamines. It works by blocking BTK to modulate B-cell and innate immune cell activity and neuroinflammation. The FDA approved the CSU indication on September 30, 2025; the European Union on April 23, 2026; and Japan's Ministry of Health, Labour and Welfare via PMDA review on June 19, 2026. The MS indication is still in the Phase 3 completion stage, and Novartis plans to submit global regulatory applications. The global MS treatment market is estimated to be worth $21–27.4 billion in 2025, and Jefferies forecasts remibrutinib's peak annual sales in MS to exceed $3 billion.
The success of two Phase 3 trials with data from approximately 2,000 patients elevates remibrutinib to a key late-stage pipeline candidate in the $21–27.4 billion global MS market in 2025. In the short term, the ARR, 3mCDP, 6mCDP, and major adverse event data to be presented at MSToronto will determine remibrutinib's relative value compared to Roche's (RHHBY) Phase 3 fenebrutinib and standard-of-care Ocrevus. In the medium to long term, if liver safety signals are maintained, remibrutinib could mitigate the class risks left by evobrutinib and Cenrifki, supporting a peak annual sales scenario of over $3 billion. From a research and business development perspective, whether BTK-mediated peripheral B-cell and central neuroinflammation modulation can extend beyond relapse suppression to delay disability progression will be critical for the subsequent SPMS Phase 3 REMASTER trial and the overall franchise value.
Source: BioPharma Dive (rss)